Walding, Andrew
Skaltsa, Konstantina
Casamayor, Montserrat
Rydén, Anna
Clinical trials referenced in this document:
Documents that mention this clinical trial
Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions
https://doi.org/10.1007/s11136-022-03088-0
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
https://doi.org/10.1007/s11523-021-00794-6
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 10 January 2022
First Online: 31 January 2022
Change Date: 24 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11136-022-03128-9
Declarations
:
: AW and AR are employees of AstraZeneca and hold AstraZeneca shares. KS and MC are employed by IQVIA, which received funds from AstraZeneca to conduct the time-to-deterioration analysis of the study data.
: The FLAURA study was approved by the institutional review board and/or independent ethics committee associated with each study centre.
: All patients in the FLAURA study provided written informed consent before any study-specific procedures were performed.
: Not applicable.